Latest:
Dr. Concin on the Patient Population in the LIO-1 Trial in Advanced Gynecologic Malignancies
Nicole Concin, MD, discusses the patient population that enrolled in the phase 1b/2 LIO-1 trial in advanced gynecologic malignancies.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Chunyan Lan, MD, PhD
Chunyan Lan, MD, PhD, is from the Department of Gynecologic Oncology at Sun Yat-sen University Cancer Center
Latest:
Dr Lan on the Efficacy of Cadonilimab Plus Lenvatinib in Advanced Endometrial Cancer
Chunyan Lan, MD, PhD, discusses data with cadonilimab plus lenvatinib in advanced endometrial cancer, as well as next steps for evaluating the combination.
Monica H. Vetter, MD
Latest:
Dr Vetter on the Role of Trial Inclusion Criteria on Coverage for Pembrolizumab- and Dostarlimab-Based Regimens in Endometrial Cancer
Monica H. Vetter, MD, on the implications for inclusion criteria for insurance approvals for pembrolizumab- and dostarlimab-based regimens in endometrial cancer.
Rino S. Seedor, MD
Latest:
Dr. Seedor on Treatment Sequencing in Metastatic Melanoma
Rino S. Seedor, MD, discusses findings from the phase 3 DREAMseq trial, which solidified up-front immunotherapy followed by targeted therapy upon progression as a standard of care in patients with BRAF V600–mutant metastatic melanoma.
Rohit Jain, MD, MPH
Latest:
Dr. Jain on Efficacy With Maintenance Avelumab Plus BSC in Metastatic Urothelial Cancer
Rohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.
Andrea A. Moreira, MD
Latest:
Breast Nerve Preservation and Grafting: How Surgeons Can Help Mitigate Sensation Loss
More surgeons are having in-depth conversations with their patients with breast cancer and prophylactic patients about the fact that nerves will have to be cut during their mastectomy, how that will impact sensation and quality of life, and how surgeon collaboration and breast neurotization can help restore sensation.
Toon Van Gorp, MD, PhD
Toon Van Gorp, MD, PhD, a gynecologic oncologist at Universitair Ziekenhuis Leuven in Belgium.
Latest:
Dr Van Gorp on the Role of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer
Toon Van Gorp, MD, PhD, discusses the significance of mirvetuximab soravtansine as treatment for FRα-positive, platinum-resistant ovarian cancer.
Howard Colman, MD, PhD
Howard Colman, MD, PhD, is the Jan M. Huntsman Presidential Professor in the Department of Neurosurgery, member of the Brain Tumor Research Team, and leader of the Center for Neurologic Cancers at Huntsman Cancer Institute, of the University of Utah.
Latest:
Dr Colman on Outcomes With Eflornithine in Grade 3 Anaplastic Astrocytoma
Howard Colman, MD, PhD, discusses the STELLAR trial of eflornithine plus lomustine vs lomustine alone in recurrent, IDH-mutant, anaplastic astrocytoma.
Satya (Nanu) Das, MD, MSCI
Latest:
Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome
Drs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.